An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients With Recurrent Platinum Sensitive Ovarian Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
response rate
GSK Clinical Trials, MD, PhD
Study Director
GlaxoSmithKline
Canada: Health Canada
104864/627
NCT00061308
December 2002
Name | Location |
---|---|
GSK Investigational Site | Bakersfield, California 93309 |
GSK Investigational Site | Gainesville, Florida 32610 |
GSK Investigational Site | St. Louis, Montana 63110 |
GSK Investigational Site | Raleigh, North Carolina 27609 |
GSK Investigational Site | Savannah, Georgia 31405 |
GSK Investigational Site | Park Ridge, Illinois 60068 |
GSK Investigational Site | Royal Oak, Michigan 48073 |
GSK Investigational Site | Pittsburgh, Pennsylvania 15213 |
GSK Investigational Site | Columbia, South Carolina 29210 |
GSK Investigational Site | Germantown, Tennessee 38138 |
GSK Investigational Site | New York, New York 10021 |
GSK Investigational Site | Washington, District of Columbia 20307-5001 |
GSK Investigational Site | Hattiesburg, Mississippi 39401 |